US M&A and equity raisings

3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds

Deals dated after 30 September 2026 are still being collected.

Deal size
Custom range

8 deals · US$373mdisclosed · Pharmaceutical Manufacturing · Clear

Columns
US M&A deals and equity raisings
Date Target Vendor Acquirer Type Status Value US$m Sector Advisers
Jun 2025 Felix Pharmaceuticals Pvt –Advent InternationalStakeAnnounced–Animal Health+2 A&L Goodbody LLPLincoln International (sell-side)Guggenheim Securities (buy-side)
Sep 2025 Zentiva Advent InternationalGTCRAcquisitionAnnounced–Pharma+1 Goldman Sachs (sell-side)PJT Partners (sell-side)Freshfields (sell-side)Barclays (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side)
Jan 2026 Nivagen Pharmaceuticals –PAI PharmaAcquisitionAnnounced–Pharmaceutical Manufacturing+1 Bourne Partners (buy-side)Kirkland & Ellis (buy-side)KPMG (buy-side)
Mar 2026 Lonza Capsules & Health Ingredients division Lonza Group AGLone Star FundsAsset saleAnnounced–Pharmaceutical Manufacturing+2 Kirkland & Ellis (buy-side)
Mar 2026 Manufacturing facility in Phoenix, AZ Bristol Myers SquibbRoviAsset saleCompleted–Pharmaceutical Manufacturing+1 William Blair
May 2026 MacroGenics GMP manufacturing site and CDMO operations MacroGenicsBora Pharmaceuticals Co.Asset saleCompleted122.5Pharmaceutical Manufacturing+1 Moelis & Company (sell-side)Sidley Austin (sell-side)Covington & Burling (sell-side)Jones Day (buy-side)
May 2026 AmbioPharm –CordenPharmaAcquisitionAnnounced–Pharma Services+2 Kirkland & EllisBNP Paribas (sell-side)Latham & Watkins (buy-side)
Jul 2026 Lannett –AurobindoAcquisitionCompleted250.0Pharma+1 Raymond JamesSullivan & Cromwell (buy-side)

Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built